ARCHIVES

NCI Programs: Advisors Approve Recompetition of Phase II Contracts

This article is from The Cancer Letter archive.

Vol. 25 No. 27 | July 9, 1999

Download PDF Visit The Full Archive

Related Articles

AVEO’s Tizozanib Fails in Colorectal Cancer

January 10, 2014

Seattle Institutions Win $16 Million In Grants For Comparative Effectiveness Research

October 16, 2009

DCT Advisors Approve Five Trials For High Priority Status

April 7, 1995

NCI Outlines Need For $3,873 Billion To Seize Cancer Research Opportunities

October 30, 1998

Study: Oncotype DX Score Can Predict Local Recurrence

March 29, 2013

House Panel Provides NCI $1.7 Billion for 1991, Expects Greater Emphasis On Cancer Prevention

July 20, 1990